The History of Testosterone Replacement Therapy

Introduction: Why Testosterone Replacement History Matters

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting or changing any hormone therapy.

If you've been researching low testosterone or considering hormone therapy, you may have wondered how we got here. The testosterone replacement history stretches back nearly two centuries, beginning with bold experiments and evolving into one of the most carefully studied hormone therapies in modern medicine. Understanding where TRT came from helps put today's treatments in clear perspective — and gives you confidence that the therapy available now is backed by generations of scientific refinement.

Testosterone is the primary male sex hormone, responsible for energy, libido, muscle mass, bone density, mood, and much more. When levels fall below optimal ranges, the effects on daily life can be significant. If you're experiencing symptoms like fatigue, low drive, or mood changes, you're not alone — and men have been seeking solutions for far longer than most people realize. You can take the free Low T symptom quiz to get a clearer picture of where you stand before speaking with a provider.

Early Experiments: The 19th-Century Roots of Hormone Therapy

The story of testosterone replacement history begins not in a modern clinic but in the eccentric laboratories of Victorian-era scientists. In 1849, German physiologist Arnold Berthold conducted one of the first recorded endocrine experiments, transplanting rooster testes into castrated birds. He observed that the transplanted glands preserved the roosters' secondary sexual characteristics — crowing, aggression, and comb growth — even without nerve connections. This demonstrated that the testes produced something circulating in the blood that influenced the whole body, a revolutionary insight for its time.

Decades later, in 1889, French neurologist Charles-Édouard Brown-Séquard made headlines across the world by injecting himself with a liquid extract made from guinea pig and dog testes. At 72 years old, he reported dramatic improvements in energy, strength, and mental clarity. While his claims were almost certainly the result of placebo effect — the crude extracts contained virtually no active hormone — his self-experimentation ignited serious scientific curiosity about what the testes were actually secreting.

Brown-Séquard's announcement sparked a wave of interest in what researchers called "organotherapy" — the idea that extracts from animal organs could treat human deficiencies. Though most of these early preparations were ineffective, they planted the conceptual seed that male vitality was hormonally driven and potentially restorable. Scientists began competing to isolate the precise substance responsible.

This era laid the philosophical groundwork for everything that followed. The concept that hormones could be extracted, synthesized, and used therapeutically was radical in the 1800s. By the early 20th century, it had become one of the most active research frontiers in medicine. To understand what testosterone replacement therapy really is today, it helps to appreciate just how far the science has come since those early animal-extract experiments.

The Isolation of Testosterone: A Landmark Decade (1930s)

The 1930s were the defining decade in testosterone replacement history. Three independent research teams — working in Germany, the Netherlands, and Switzerland — raced to isolate and synthesize the male sex hormone from animal sources. The competition was fierce, scientifically rigorous, and ultimately Nobel Prize-worthy.

In 1931, Adolf Butenandt isolated androsterone from male urine, providing the first purified male hormone compound. Then, in 1935, Dutch chemist Ernst Laqueur and his team at the University of Amsterdam isolated testosterone itself from bull testes, publishing their findings in the journal Nature. They named the compound "testosterone" from the Latin words for testes and sterol. In the same year, both Butenandt and Leopold Ruzicka independently synthesized testosterone from cholesterol — a critical milestone because it meant the hormone no longer needed to be extracted from animal organs in limited quantities.

Ruzicka and Butenandt shared the Nobel Prize in Chemistry in 1939 for this work. Their synthesis made testosterone available in quantities sufficient for human experimentation, and clinical studies began almost immediately. Early clinical applications focused on men who had undergone surgical castration or had hypogonadism due to injury or disease — conditions where testosterone deficiency was severe and unmistakable.

The 1930s also saw the first injectable testosterone preparations, including testosterone propionate, which had a short duration of action requiring frequent injections. These early formulations were far from perfect, but they confirmed the fundamental clinical principle: restoring testosterone levels could meaningfully improve quality of life in men with documented deficiency. The foundation of modern hypogonadism treatment was officially laid.

Mid-20th Century: Refinement of Delivery Methods

With testosterone successfully synthesized, researchers turned their attention to a practical challenge: how do you get the hormone into the body efficiently and safely? The history of testosterone delivery methods is itself a rich chapter in the broader testosterone replacement history.

Testosterone propionate, introduced in the late 1930s, required injections every two to three days — inconvenient for long-term therapy. In the 1950s, longer-acting esters were developed. Testosterone enanthate (introduced around 1954) and testosterone cypionate allowed for weekly or biweekly injections, dramatically improving patient adherence. These two esters remain among the most widely used forms of injectable TRT today. You can read more about testosterone cypionate vs enanthate to understand how each works in modern protocols.

Subcutaneous testosterone pellets were also developed during this era. Implanted under the skin, pellets slowly released testosterone over three to six months, offering a hands-free alternative to injections. While pellets fell out of mainstream use for several decades, they have seen a significant resurgence in recent years. Our full comparison of testosterone injections vs pellets breaks down the modern tradeoffs between these approaches.

Oral testosterone formulations were another area of mid-century research. Methyltestosterone, an oral compound developed in the 1930s, was used clinically for decades, though it carried liver toxicity concerns with long-term use. Later modifications led to safer oral options, though injectable and topical routes remained preferred for most patients. Today's oral testosterone options — including Jatenzo and Kyzatrex — use advanced absorption technology that avoids first-pass liver metabolism entirely.

By the 1960s and 1970s, testosterone therapy had become a recognized clinical treatment, particularly for men diagnosed with primary hypogonadism (testicular failure) or secondary hypogonadism (pituitary/hypothalamic dysfunction). The patient population was relatively narrow by modern standards — treatment was largely reserved for men with clearly documented, severe deficiencies rather than age-related decline.

The Late 20th Century: Expanding Understanding and Broader Use

The 1980s and 1990s represented a turning point in how medicine understood testosterone's role across the male lifespan. Research during this period began documenting the natural decline in testosterone that occurs with aging — a process now sometimes called andropause or late-onset hypogonadism. Studies consistently showed that average testosterone levels in men fall approximately one to two percent per year after age thirty, with a more pronounced decline after age forty-five.

This research prompted a broader clinical conversation: if testosterone deficiency could cause significant symptoms in younger men with testicular failure, could age-related decline cause similar problems in older men? The question fueled a wave of clinical trials throughout the 1990s examining testosterone therapy's effects on muscle mass, bone density, sexual function, mood, and cognitive performance in aging men.

A major development during this period was the introduction of transdermal testosterone. The first testosterone patch (Testoderm) was approved by the FDA in 1993, followed by Androderm in 1995. These patches allowed for daily dosing that more closely mimicked the body's natural circadian rhythm of testosterone production. Testosterone gels followed in 2000 with the approval of AndroGel, which quickly became one of the most prescribed testosterone products in the United States. These topical options made TRT far more accessible and comfortable for patients who were uncomfortable with injections. You can explore the nuances of TRT gel vs patches to see how these delivery methods compare today.

This era also saw growing awareness of the symptoms associated with low testosterone — fatigue, reduced libido, erectile dysfunction, mood changes, and body composition shifts. For men who recognized these symptoms, understanding that they might have a treatable hormonal cause was a meaningful development. If any of this sounds familiar, reviewing the 10 signs of low testosterone in men can be a useful first step before consulting a provider.

The 2000s: Mainstream Medicine, Controversy, and Regulation

The early 2000s saw TRT become truly mainstream. Testosterone prescriptions in the United States increased more than tenfold between 2000 and 2013, driven by direct-to-consumer advertising, growing awareness of hypogonadism, and the development of convenient delivery forms like gels and patches. This rapid growth attracted both clinical enthusiasm and regulatory scrutiny.

In 2010 and 2014, two large observational studies raised questions about potential cardiovascular risks associated with testosterone therapy in older men or men with pre-existing heart conditions. These studies generated significant media coverage and prompted the FDA to require label changes on testosterone products in 2015, mandating warnings about possible cardiovascular risks and clarifying that products were approved only for men with low testosterone due to a medical condition — not normal aging alone.

It is important to note that these early studies had significant methodological limitations, and subsequent research has provided a much more nuanced picture. The landmark TRAVERSE trial, published in 2023, was specifically designed to evaluate cardiovascular safety in men with hypogonadism and found that testosterone therapy was not associated with increased cardiovascular events compared to placebo. For a thorough, balanced review of what the evidence actually shows, see our article on TRT safety including heart and prostate considerations.

The regulatory environment during this decade also clarified the distinction between medically supervised TRT for diagnosed hypogonadism and the unsupervised use of anabolic steroids for performance enhancement. These are fundamentally different practices — TRT aims to restore hormones to a normal physiological range, while anabolic steroid abuse involves supraphysiological doses for athletic performance. The article Is TRT a Steroid? clarifies these important distinctions.

The 2010s–2020s: Personalized Medicine and the TRT Renaissance

The most recent chapter in testosterone replacement history has been defined by personalization, precision, and expanded access. Advances in laboratory testing, telehealth platforms, and a growing body of clinical evidence have transformed TRT from a relatively niche endocrine treatment into a widely available, well-managed therapy for hundreds of thousands of men.

Comprehensive hormone panels became the standard of care, allowing providers to evaluate not just total testosterone but free testosterone, estradiol, SHBG, LH, FSH, hematocrit, PSA, and other markers that inform individualized treatment decisions. Understanding the difference between free vs total testosterone is now considered fundamental to proper TRT management. Similarly, monitoring markers like hematocrit during TRT is a routine part of safe, responsible care.

New delivery methods continued to emerge. Nasal testosterone gel (Natesto) was approved in 2014. Oral testosterone undecanoate formulations — Jatenzo (2019) and Kyzatrex (2022) — offered genuinely liver-safe oral options for the first time, using a lymphatic absorption pathway to bypass first-pass metabolism. Subcutaneous testosterone pellets also experienced a major clinical revival, with several specialized pellet-insertion services expanding across the country.

The rise of telemedicine transformed access to TRT dramatically. Men in rural or underserved areas who previously had no access to hormone specialists could now consult with qualified TRT providers from home, receive lab orders, and have medications shipped directly. If you're exploring your options, you can find a TRT clinic near you or browse the best telemedicine TRT providers available today. The parallel rise of specialized TRT clinics also gave men more options for focused, experienced care compared to a general practitioner who might see only a handful of low-T cases per year.

This era also produced the most rigorous clinical trial in TRT history: the Testosterone Trials (TTrials), a coordinated series of seven double-blind, placebo-controlled studies funded by the NIH and published between 2016 and 2018. These trials demonstrated that testosterone therapy significantly improved sexual function, physical performance, bone density, and mood in men over 65 with confirmed hypogonadism — providing the clearest evidence yet that TRT offers meaningful, measurable benefits when properly indicated.

How Modern TRT Protocols Reflect Decades of Scientific Learning

Every aspect of how a reputable TRT provider manages your therapy today reflects lessons learned across nearly a century of clinical experience. Screening protocols, monitoring schedules, dosing strategies, and adjunct medications all exist because earlier generations of clinicians identified what could go wrong and developed systematic solutions.

For example, the routine monitoring of estradiol during TRT stems from decades of understanding that testosterone aromatizes to estrogen in the body, and that managing this conversion is important for symptom control and overall wellbeing. Medications like anastrozole are used selectively when estrogen rises excessively — you can learn more in our article on anastrozole on TRT. Similarly, the use of HCG alongside TRT to preserve testicular function and fertility reflects hard-won clinical knowledge about how exogenous testosterone affects the hypothalamic-pituitary-gonadal axis. Our guide to HCG and TRT explains this relationship in full.

Modern providers also conduct thorough intake evaluations that would have been unimaginable to the pioneers of the 1930s. Before starting therapy, a qualified provider will review your symptoms, medical history, cardiovascular risk factors, prostate health, sleep patterns, and a comprehensive blood panel. This careful approach means that TRT today is safer, more effective, and more precisely tailored than at any previous point in its history. You can review exactly what to expect at your first TRT consultation.

The range of available protocols has also expanded significantly. Men can now choose between weekly injections, twice-weekly injections, subcutaneous administration, daily gels, patches, nasal gel, oral capsules, or long-acting pellets — each with different pharmacokinetic profiles suited to different lifestyles and physiologies. Understanding TRT injections vs gel is a practical decision modern patients can make in consultation with their provider, backed by solid comparative data.

The Future of Testosterone Therapy and What It Means for You

The testosterone replacement history is far from over. Current research is actively exploring several exciting frontiers: selective androgen receptor modulators (SARMs) that could offer tissue-specific benefits with fewer systemic effects, improved long-acting injectable formulations, and a better understanding of how testosterone interacts with metabolic health, cognitive aging, and longevity.

Combination therapies are also an active area of investigation. Clinicians are increasingly exploring how TRT interacts with other treatments such as GLP-1 medications like Ozempic for metabolic optimization, as well as peptide therapies for enhanced recovery and body composition. The intersection of hormone optimization with broader men's health and longevity medicine is one of the fastest-evolving areas in clinical practice.

Regulatory clarity continues to improve as well. Professional organizations including the American Urological Association, the Endocrine Society, and the American Association of Clinical Endocrinology have all published updated clinical guidelines in recent years that provide clearer, evidence-based frameworks for diagnosing and treating hypogonadism. These guidelines help ensure that men who genuinely need TRT can access it, while also protecting against unnecessary prescribing.

Perhaps most importantly for you as someone researching your options: the decades of testosterone replacement history mean that today's therapy is built on an enormous foundation of clinical knowledge. The protocols, the monitoring, the safety considerations — all of it has been refined through generations of careful scientific work. TRT is not an experiment; it is an established, FDA-recognized medical treatment with a deep evidence base. If you're experiencing symptoms that might point to low testosterone, the right next step is to consult with a qualified provider who can evaluate your individual situation. You can take the free Low T symptom quiz to assess your symptoms, then find a TRT clinic near you to take the next step toward feeling your best.